Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ibrahim, Z. H. Z.
Right arrow Articles by Lieberman, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ibrahim, Z. H. Z.
Right arrow Articles by Lieberman, B. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 5, No. 3, pp. 258-262, 1990
© 1990 European Society of Human Reproduction and Embryology

research-article

Use of buserelin in an FVF programme for pituitary —- ovarian suppression prior to ovarian stimulation with exogenous gonadotrophins

Z. H. Z. Ibrahim, P. L. Matson1, P. Buck, J. D. Critchlow, M. C. Newman, G. Horne, S. Hughes and B. A. Lieberman

Regional IVF Unit St. Mary's Hospital Whitworth Park Manchester M13 OJH, UK

Correspondence: 1To whom correspondence should be addressed

Daily s.c. injections of buserelin were commenced in the midluteal phase of the preceding cycle in 118 women undergoing in-vitro fertilization (TVF) and embryo transfer. Ovarian and pituitary suppression was said to have been adequately achieved when serum oestradiol was <50 pg/ml, serum LH <2.0 IU/1, no ovarian cysts ≥10 mm diameter were present and menstruation had occurred. Nine groups of women were retrospectively identified after the administration of buserelin for 12 days according to whether pituitary and ovarian suppression had been achieved or not, and the reason for extended buserelin treatment prior to ovarian stimulation. Upon adequate suppression, patients were grouped in terms of the duration of exposure to buserelin, and ovarian stimulation was then started by daily injections of human menopausal gonadotrophin. There appeared to be no differences in the ovarian response for women down-regulated by day 12,19 or ≥26 days; those women requiring extended buserelin treatment did equally well compared to those women down-regulating quickly, in terms of number of oocytes recovered and fertilization rate. Clinical pregnancy rates per embryo transfer were 27/68(40%), 8/33(26%) and 4/17(24%) for those women down-regulated by days 12, 19 or ≥26 respectively, and were not significantly different.

Key words: GnRH agonist/in-vitro fertilization/ovarian


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
T. J. Child, C. Sylvestre, and S. L. Tan
Endometrial volume and thickness measurements predict pituitary suppression and non-suppression during IVF
Hum. Reprod., December 1, 2002; 17(12): 3110 - 3113.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. Yaman, T. Ebner, M. Sommergruber, J. Hartl, W. Polz, and G. Tews
Three-dimensional endometrial volume estimation as a predictor of pituitary down-regulation in an IVF-embryo transfer programme
Hum. Reprod., August 1, 2000; 15(8): 1698 - 1702.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.